TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa infection.~* Male and female subjects between 6 and 21 years of age at the time of screening.~* FEV1 at screening must be between 25% and 80% of normal predicted values.~Exclusion Criteria:~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Accuracy of the 64 Slices Computed Tomography for the Diagnosis of Left Atrial Appendage Thrombus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients hospitalized at BICHAT hospital and referred for a TEE clinically motivated by search of a LAA thrombus~* 18 years old~* signed informed consent 3 hours after TEE,~* Have health insurance.~Exclusion Criteria:~* woman into old of procreates~* impaired renal function~* Renal Hypoperfusion~* drugs nephrotoxic~* myeloma~* iodine injection 48 h before the inclusion~* over-sensitiveness with a product of iodized contrast~* Contra-indication for CT with iodine injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thrombus (Type: ACTIVE_COMPARATOR): patients with positive TEE (thrombus)
- No thrombus (Type: PLACEBO_COMPARATOR): patients with negative TEE (no thrombus)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who underwent CABG and/or cardiac valve surgery involving cardiopulmonary bypass and develop postoperative atrial fibrillation within 7 days after surgery~Exclusion Criteria:~* Subjects who had any form of atrial fibrillation prior to surgery~* Subjects who were on antiarrhythmic medications preoperatively, including but not limited to procainamide and amiodarone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Amiodarone with cardioversion (Type: OTHER): If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously untreated AML (\>/= 20% blasts) or AML M6. Patients with high-risk (intermediate-2 or high by IPSS or \>/= 10% blasts) MDS will also be eligible. Prior therapy with hydroxyurea, biological or targeted therapy (e.g. flt3 inhibitors, other kinase inhibitors, azacitidine), or hematopoietic growth factors is allowed. No prior chemotherapy is allowed except for a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use is also allowed as prior therapy.~2. Age \>/= 70 years.~3. Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.~4. Adequate hepatic (serum total bilirubin \</= 1.5 x ULN, serum glutamate pyruvate transaminase (SGPT) and/or SGOT \</= 2.5 x ULN) and renal function (creatinine \</= 2.0 mg/dL).~5. Patients must be willing and able to review, understand, and provide written consent before starting therapy.~6. Men of childbearing potential who agree to use contraception prior to study entry and for the duration of participation.~Exclusion Criteria:~1. New York Heart Association (NYHA) class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension (blood pressure \>/= 160 systolic and \>/= 110 diastolic not responsive to antihypertensive medication), uncontrolled diabetes mellitus, or congestive heart failure.~2. Myocardial infarction in the previous 12 weeks (from the start of treatment).~3. Active and uncontrolled disease/infection as judged by the treating physician.~4. Acute promyelocytic leukemia (APL).

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omacetaxine + Decitabine (Type: EXPERIMENTAL): Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older with at least one blood culture positive for S. aureus within 48 hours before randomization~* At least one of the following signs or symptoms of bacteremia:~  * Temperature ≥ 38.0°C~ * White blood cell (WBC) count \> 10,000 or \< 4,000 cells/µL or \> 10% immature neutrophils (bands)~ * Tachycardia (heart rate \> 90 bpm)~ * Tachypnea (respiratory rate \> 20 breaths/min)~ * Hypotension (systolic blood pressure \< 90 mmHg)~ * Signs or symptoms of localized catheter-related infection~* At enrollment, subjects must have either 1) known right-sided infective endocarditis by Modified Duke's criteria 2) known complicated bacteremia, demonstrated as signs or symptoms of metastatic foci of S. aureus infection or 3) at least one risk factor for complicated bacteremia.~Exclusion Criteria:~* Treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 60 hours within 7 days before randomization. EXCEPTION: Documented resistance to the prior systemic antibacterial therapy~* Presence of an infection source that will not be managed or controlled within the first 3 days of study drug treatment~* Presence of prosthetic cardiac valve or cardiac device (eg, implantable cardioverter defibrillator \[ICD\]), permanent pacemaker, or cardiac valve support ring)~* Known or suspected left-sided infective endocarditis (LIE), by Modified Duke Criteria. NOTE: Right-sided infective endocarditis (RIE) is permitted~* Known or suspected osteomyelitis or meningitis. NOTE: Evidence of metastatic complications related to the primary infection such as right-sided endocarditis, septic arthritis, septic pulmonary emboli are permitted. S. aureus pneumonia is permitted~* Confirmed evidence (identification or gram stain) of a mixed polymicrobial infection with a Gram-negative pathogen that requires non-study antibiotic treatment with agent(s) that have activity against Gram-negative pathogens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telavancin (Type: EXPERIMENTAL): 7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
- Standard of care (Type: ACTIVE_COMPARATOR): Vancomycin, Daptomycin, synthetic penicillin or Cefazolin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older.~2. Both male and female~3. Within 24 hours from admission.~4. Having 25 -Hydroxyvitamin D level of 12 ng/ml or lower.~Exclusion Criteria~1. Pregnant or lactating females.~2. Do not resuscitate (DNR) status or comfort measures only~3. No consent~4. Severely impaired gastrointestinal functions (e.g, paralytic ileus, continuous nasogastric tube drainage, strict nil per oral- no medication, malabsorption syndrome, chronic diarrhea etc)~5. History of renal stones within past year~6. Past history of hypercalcemia, tuberculosis or sarcoidosis.~7. Baseline serum total calcium ≥10.6 mg/dl or ionized serum calcium ≥ 5.4 mg/dl.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol (Type: EXPERIMENTAL): This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
- Placebo (Type: PLACEBO_COMPARATOR): This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature (Appendix Informed Consent Form)~* Preexcitation in resting ECG (WPW ECG Pattern)~* Age between 8 and 18 years~* Invasive EPS must be indicated/planned at the Children's Hospital Zurich~Exclusion Criteria:~* Inability to follow the procedures of the study, e.g. due to language problems or psychological disorders of the participant~* Inability to walk/run on a treadmill

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Stress ECG Test (Type: EXPERIMENTAL): The whole study cohort undergoes the same diagnostic workup including stress test (ECG)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Single-Stage Integra Reconstruction in Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking adult burn patients greater than 18 years old, admitted with burn injuries eligible for Integra® reconstruction at the discretion of the burn attending physicians.~Exclusion Criteria:~* patients with isolated hand or face burns - these burns are treated with sheet grafts (unmeshed); the 3:1 mesh grafts would not be used on these cosmetically sensitive areas. If they have hand and/or face burns in addition to other areas, they will not be excluded. However, the study itself will not be performed on the hands or face. Additionally, patients unable to present to our clinic for routine follow-up due to geographic limitations or otherwise will be ineligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 125 Years
- Healthy Volunteers: f

Study Arms:
- Single-stage Integra (Type: EXPERIMENTAL): Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: DIATOR-Diabetes Intervention With Atorvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment~* Age 18 to 39 years, inclusive~* Male patient or female patient using adequate contraceptive methods~* Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA~Exclusion Criteria:~* History of a malignancy~* Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated more than ten percent above the upper limit of normal, elevation of AST or ALT more than 3 times the upper limit of normal~* Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator~* Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin~* Pregnant or nursing women or women intending to become pregnant~* Known or suspected allergy to atorvastatin or any component of thr trial product~* Known myopathy, myalgia or myositis with a serum-CPK above 3 times the upper limit of normal~* Patients who had a severe blood loss (\>= 400 mL, e.g. blood donation) within 2 months prior to visit 2~* Any significant laboratory abnormality~* A serum LDL-cholesterol above 150 mg/dL at time of screening~* Unwillingness to comply with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- atorvastatin matching placebo (Type: PLACEBO_COMPARATOR): atorvastatin matching placebo
- atorvastatin (Type: EXPERIMENTAL): 40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3, 4 or 5); duration of intermittent claudication (category 1-3) should be at least 6 months~2. The patient should be suitable for percutaneous transluminal angioplasty (PTA) and also for stenting.~Exclusion Criteria:~1. Poor aortoiliac or common femoral inflow, which would be deemed inadequate to support a femoropopliteal bypass graft.~2. Patient having total occlusions or severe stenosis of the iliac artery on the same side must be excluded.~3. Gangrene in index limb (Rutherford category 6).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cordis SMART™ Nitinol Stent
- 2 (Type: ACTIVE_COMPARATOR): balloon angioplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High-Density Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic intractable pain who meets the Korean SCS Reimbursement Guideline as follows:~   (Korea SCS Reimbursement Guideline)~  1. An ineffective patient with sustainable severe intractable pain (VAS or NRS pain score over 7 grade) who has been treated by a conservative therapy (medication and nerve block, etc.) for 6 months. cf.) CRPS is available after the conservative therapy for 3 months~  2. An ineffective cancer pain patient with over 1-year life expectancy and VAS (or NRS pain score) over 7 grade who takes active pain treatment for 6 months such as medication, nerve block, epidural morphine injection, etc.~2. Age \> 18~3. Patients who have been informed of the study procedures and has given written informed consent.~4. Patients who are willing to comply with study protocol including attending the study visits~Exclusion Criteria:~1. Expected inability of patients to receive or properly operate the SCS system~2. Active malignancy~3. Addiction to any of the following drugs, alcohol, and/or medication~4. Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by investigator~5. Local infection or other skin disorder at site of incision~6. Pregnancy~7. Other implanted active medical device~8. Life expectancy \< 1 year~9. Coagulation deficiency (Platelet count \< 100,000, PT INR \> 1.4)~10. Immune deficiency (HIV positive, immunosuppressive, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group C spinal cord stimulator (Type: EXPERIMENTAL): Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
- Group H spinal cord stimulator (Type: ACTIVE_COMPARATOR): Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Complex Regional Pain Syndrome in Children: Impact of Bergès Relaxation on the Autonomic Balance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parents affiliates or entitled to a social security scheme~* Children from 6 to 16 years with Complex Regional Pain Syndrome (CRPS) type 1~* Diagnosis according to the Budapest criteria.~Exclusion Criteria:~* Child with pathologies reaching the central nervous system or the brain stem.~* Children with a severe pathology of cardio-respiratory or heart being referred to treatment.~* Children requiring emergency surgery or trauma or septic or inflammatory context.~* Children with some psychiatric diseases~* Children who no understand french enough

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Complex Regional Pain Syndrome (CRPS) (Type: EXPERIMENTAL): Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Femoral Nerve Block in Children With a Femur Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A child with a femoral shaft fracture requiring surgical treatment and the placement of intramedullary nails~* Weight of 30-100 Kg~* Child must be older than 6 years old~Exclusion Criteria:~* Any child that had an open fracture~* A child that has a pain abnormality~* Any child with an allergy to local anesthetic~* Any child with a neurological injury~* Any child with the inability to report pain~* Any child that is unable to use a PCA post-operatively

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- PCA only (Type: NO_INTERVENTION): this group will only get a pain control anesthesia pump to use for post-operative pain
- PCA and femoral nerve block (Type: EXPERIMENTAL): this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
- PCA + hematoma block (Type: EXPERIMENTAL): patient will receive hematoma block during surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues